Clinical trials: Pediatric HIV Infection
Human Immunodeficiency Virus, HIV
Nevirapine Dosing in Neonates for Prophylaxis of Mother-to-Child-Transmission (MTCT) of HIV Infection
The purpose of this study is to determine whether the current dose of nevirapine recommended in the Ontario Ministry of Health vertical transmission prevention protocol achieves therapeutic drug levels in newborn infants at high…
- Conditions
- Human Immunodeficiency Virus, HIV, Vertical Infection Transmission
- Trial name
- NCT02166502
- Where
- 2 sites in Canada
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- The Hospital for Sick Children
Acquired Immunodeficiency Syndrome
Chinese Network of Pediatric Antiretroviral Therapy
This is an observational cohort in pediatric HIV patients in China. Children who receive antiretroviral drugs will be recruited in this study. The main objectives are as follows: 1.
- Trial name
- CN-PART (NCT01210924)
- Where
- China
- Volunteers
- 400 people
- Sponsor
- National Center for AIDS/STD Control and Prevention, China CDC
HIV Infections
The Safety and Effectiveness of Two Forms of Saquinavir Combined With Other Anti-HIV Drugs in HIV-Infected Infants and Children
To determine the pharmacokinetic properties, tolerance and safety of 2 formulations of saquinavir, given in combination with 2 nucleoside antiretroviral drugs (part 1) or in combination with nelfinavir and nucleoside…
- Trial name
- NCT00002380
- Testing
- Nelfinavir mesylate, Saquinavir
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Hoffmann-La Roche
Pediatric HIV Infection, Tuberculosis Infection
Dolutegravir Pharmacokinetics Among HIV/TB Coinfected Children Receiving Standard and High-dose Rifampicin
Tuberculosis (TB) is the leading cause of death among children with HIV, yet insufficient data are available on the pharmacokinetics of newer HIV/TB cotreatment strategies in children.
- Trial name
- NCT05069688
- Testing
- rifampicin
- Where
- Nigeria
- Volunteers
- 20 people
- Sponsor
- Brigham and Women's Hospital
Tuberculosis, HIV Coinfection
Closing -TB GAPs - for People Living With HIV: TB Guidance for Adaptable Patient-Centered Service
Tuberculosis (TB) is the world's leading infectious cause of mortality and responsible for 1/3 of deaths in people living with human immunodeficiency virus (PLHIV).
- Conditions
- Tuberculosis, HIV Coinfection, Tuberculosis Infection
- Trial name
- TB_GAPS (NCT05342064)
- Testing
- patient-centered TB preventive therapy, TB preventive therapy adherence support
- Where
- 5 sites in Eswatini, Lesotho and 3 more
- Volunteers
- 6,500 people
- Sponsor
- Baylor College of Medicine
HIV Infections
An Open-Label Study of Emtricitabine in Combination With Other Antiretroviral Agents in HIV Infected Pediatric Subjects
To obtain safety and efficacy data for antiretroviral regimens containing emtricitabine in HIV-1 infected pediatric subjects. To determine emtricitabine concentrations in HIV-1 infected pediatric subjects and, if necessary, to…
- Trial name
- NCT00642291
- Testing
- Emtricitabine
- Where
- 2 sites in Romania
- Volunteers
- 16 people
- Sponsor
- Gilead Sciences
HIV Infection
An Adaptive Platform Trial for Evaluation of Novel Treatment Regimens in Children and Adolescents With HIV in Africa
The goal of the CHAPAS-5 clinical trial is to find out how well different HIV treatments work in children and young people (from 4 weeks up to under 15 years old) living with HIV, including those starting treatment for the first…
- Trial name
- CHAPAS-5 (NCT07792096)
- Testing
- Dolutegravir (DTG), Abacavir (ABC), Lamivudine (3TC)
- Volunteers
- 800 people
- Sponsor
- University College, London
HIV Infection
Combination Drug Treatment of Pediatric HIV Infection
This study will test the safety and effectiveness of hydroxyurea, an anti-cancer drug, given together with the anti-HIV drugs didanosine, stavudine and efavirenz for treating children infected with human immunodeficiency virus…
- Trial name
- NCT00001818
- Testing
- Hydroxyurea
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
HIV
SANKOFA Pediatric HIV Disclosure Intervention
A culturally-relevant, theoretically and empirically sound, patient-centered, standardized disclosure intervention that can be integrated into routine clinical pediatric HIV care has potential to prevent transmission and improve…
- Trial name
- NCT01701635
- Testing
- Disclosure intervention, usual care
- Where
- 2 sites in Ghana
- Volunteers
- 446 people
- Sponsor
- Yale University
Paediatric HIV Diagnosis Disclosure
Pediatric HIV Disclosure Intervention
With increased availability of antiretroviral therapy (ART) and improved care, increasing numbers of perinatally infected children are surviving into adolescence.
- Trial name
- NCT01773642
- Testing
- Cognitive behavioral intervention to support pediatric HIV disclosure
- Where
- 6 sites in Uganda
- Volunteers
- 600 people
- Sponsor
- University of Connecticut
HIV Infections
Dolutegravir Study in HIV-1 Participants Completing IMPAACT Studies P1093 and P2019
Dolutegravir is a potent integrase strand transfer inhibitor. Abacavir/dolutegravir/lamivudine (ABC/DTG/3TC) is a fixed dose combination regimen containing two nucleoside reverse transcriptase inhibitors and dolutegravir.
- Trial name
- NCT03016533
- Testing
- Dolutegravir film-coated tablets, Dolutegravir film-coated dispersible tablets, ABC/DTG/3TC immediate release tablets
- Where
- 17 sites in United States, Botswana and 5 more
- Volunteers
- 100 people
- Sponsor
- ViiV Healthcare
Leukemia, Lymphoma
Interferon Alfa in Treating Children With HIV-Related Cancer
RATIONALE: Interferon alfa may interfere with the growth of cancer cells. PURPOSE: Phase II trial to study the effectiveness of interferon alfa in treating children with an HIV-related cancer including leukemia, non-Hodgkin's…
- Conditions
- Leukemia, Lymphoma, Unspecified Childhood Solid Tumor, Protocol Specific
- Trial name
- NCT00002621
- Testing
- recombinant interferon alfa
- Where
- 10 sites in United States, Canada and 2 more
- Volunteers
- 8 people
- Sponsor
- Children's Oncology Group
HIV Infections
Pharmacokinetics and Safety Study of Tipranavir in Combination With Low Dose Ritonavir in Human Immunodeficiency Virus (HIV)-Infected Children
The primary objective of this study is to assess the safety and tolerability of tipranavir (TPV) oral formulation and soft gelatin capsules together with low-dose ritonavir in HIV-infected children and adolescents, to provide…
- Trial name
- NCT00076999
- Testing
- TPV oral solution, RTV oral solution
- Where
- 30 sites in United States, Argentina and 8 more
- Volunteers
- 115 people
- Sponsor
- Boehringer Ingelheim
HIV Infections, HIV/AIDS
Evaluating the Feasibility of Point of Care Birth Testing in Eswatini
This study aims to assess the feasibility and utility of birth testing using point-of-care (POC) testing in maternity settings in Eswatini.
- Conditions
- HIV Infections, HIV/AIDS, Pediatric HIV Infection, Transmission, Perinatal Infection
- Trial name
- NCT04206878
- Testing
- Point-of-care birth test
- Where
- Eswatini
- Volunteers
- 3,316 people
- Sponsor
- Elizabeth Glaser Pediatric AIDS Foundation
Hiv, HIV Infections
Long-Acting Treatment in Adolescents (LATA)
The LATA trial will find out if taking a long-acting injectable form of HIV medicines, called cabotegravir and rilpivirine, every 2 month works as well as taking tablet HIV medicines every day in young people aged 12-19 years of…
- Conditions
- Hiv, HIV Infections, HIV-1-infection, Paediatric Human Immunodeficiency Virus Infection
- Trial name
- LATA (NCT05154747)
- Testing
- Cabotegravir, Rilpivirine Drug Combination, TLD
- Where
- 5 sites in Kenya, South Africa and 2 more
- Volunteers
- 476 people
- Sponsor
- University College, London
Pneumonia, Human Immunodeficiency Virus (HIV)
CPAP Improving Mortality for Pneumonia in African Children Trial
Pneumonia mortality rates in African countries like Malawi are high and increased further in children -exposed or infected with human immunodeficiency virus (HIV) as well as those that are severely malnourished or severely…
- Conditions
- Pneumonia, Human Immunodeficiency Virus (HIV), Malnutrition, Hypoxemia
- Trial name
- IMPACT (NCT02484183)
- Testing
- bubble continuous positive airway pressure (CPAP)
- Where
- Malawi
- Volunteers
- 646 people
- Sponsor
- Johns Hopkins University
Pediatric HIV Infection
Evaluating an HIV Risk Screening Tool for Orphans and Vulnerable Children in Tanzania
The goal of the research was to evaluate the performance of items within the Kizazi Kipya (K2) Orphan and Vulnerable Children (OVC) HIV risk screening tool in identifying HIV-positive children, to optimize an HIV screening tool…
- Trial name
- NCT04517760
- Where
- Tanzania
- Volunteers
- 21,080 people
- Sponsor
- Elizabeth Glaser Pediatric AIDS Foundation
HIV-1
A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Activity of Rilpivirine (TMC278) in Human Immunodeficiency Virus Infected Adolescents and Children Aged Greater Than or Equal to 6 Years
The purpose of this study is to evaluate the pharmacokinetics, safety and antiviral activity of rilpivirine (TMC278) 25 milligram (mg) or adjusted dose once daily in combination with an investigator-selected background regimen…
- Trial name
- NCT00799864
- Testing
- Rilpivirine, Zidovudine, Abacavir
- Where
- 17 sites in United States, India and 6 more
- Volunteers
- 54 people
- Sponsor
- Janssen Sciences Ireland UC
Acquired Immune Deficiency Syndrome (AIDS), HIV Infections
Two Part Study to Evaluate Pharmacokinetics, Safety, and Antiviral Activity of Elvitegravir Administered With a PI/r Background Regimen for ARV Treatment-Experienced Pediatric Participants
The primary objectives of this study are to evaluate the safety, tolerability and steady-state PK and confirm the dose of EVG/r in HIV-1 infected, antiretroviral treatment-experienced children 4 weeks to <18 years of age.
- Trial name
- NCT01923311
- Testing
- EVG, Background regimen
- Where
- 11 sites in United States, Italy and 4 more
- Volunteers
- 31 people
- Sponsor
- Gilead Sciences
HIV Infections
Routine Use of Antiretroviral Therapy to Prevent Mother-to-Child HIV Transmission in the Kafue District of Zambia
The investigators will enroll a cohort of HIV-infected pregnant women accessing PMTCT services, to better understand the incremental benefits (e.g. reduction in HIV transmission, improvements in HIV-free survival) and risks (e.g.
- Trial name
- NCT00753324
- Testing
- Routine three-drug antiretroviral prophylaxis
- Where
- Zambia
- Volunteers
- 284 people
- Sponsor
- University of North Carolina, Chapel Hill